Chemart Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 20-06-2024
- Paid Up Capital ₹ 0.10 M
as on 20-06-2024
- Company Age 4 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2022)
- Net Worth 180.34%
(FY 2022)
- Total Assets 9257.14%
(FY 2022)
About Chemart Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Saketh Pailla, Vishnu Kowkuntla, and Alla Reddy serve as directors at the Company.
- CIN/LLPIN
U52520TG2020PTC142822
- Company No.
142822
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Aug 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
K.V.Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Chemart Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Saketh Pailla  | Additional Director | 28-Dec-2021 | Current |
Vishnu Kowkuntla  | Director | 14-Aug-2020 | Current |
| Alla Reddy | Director | 14-Aug-2020 | Current |
Financial Performance and Corporate Structure Insights of Chemart Pharma.
Chemart Pharma Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth Soared by an impressive increase of 180.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Chemart Pharma?
In 2021, Chemart Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Smart Agro Industries Corporation Private LimitedActive 15 years 10 monthsSaketh Pailla and Vishnu Kowkuntla are mutual person
Sciegen Pharmaceuticals India Private LimitedActive 11 years 10 monthsSaketh Pailla and Alla Reddy are mutual person
Chemeca Drugs Private LimitedActive 21 years 2 monthsSaketh Pailla and Alla Reddy are mutual person
Bactolac Nutraceuticals Private LimitedActive 1 year 5 monthsSaketh Pailla and Alla Reddy are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Chemart Pharma?
Chemart Pharma has a workforce of 0 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Chemart Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Chemart Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
